Epicardial adipose tissue in obesity with heart failure with preserved ejection fraction: Cardiovascular magnetic resonance biomarker study

doi:10.4330/wjc.v16.i3.149

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3273)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

HTML

1630

Figures (1-3)

300

Tables (1-5)

268

Sum=2286

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

136

Download

381

Sum=517

Publishing Process of This Article

Item

Count

Browse

107

Download

262

Sum=369

Mar 26, 2024 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Cardiol. Mar 26, 2024; 16(3): 149-160
Published online Mar 26, 2024. doi: 10.4330/wjc.v16.i3.149

Table 1 Baseline characteristics and laboratory findings of the obesity in populations with and without heart failure with preserved ejection fraction, n (%)

Parameter	HFpEF+ (n = 17)	HFpEF- (n = 45)	P value
Age (yr)	42.94 ± 3.37	36.60 ± 1.80	0.0819
> 60A	3 (17.6)	1 (0.02)	0.0275^a
Male gender	11 (64.7)	25 (55.6)	0.5227
BSA (m²)	2.17 ± 0.07	2.13 ± 0.04	0.639
Weight (kg)	102.60 ± 5.49	103.00 ± 4.37	0.9667
BMI (kg/m²)	35.78 ± 1.28	33.5 ± 0.99	0.2093
Systolic blood pressure (mmHg)	139.80 ± 4.73	130.90 ± 1.84	0.0370^a
Diastolic blood pressure (mmHg)	86.59 ± 3.21	82.51 ± 1.61	0.2174
Complications
Diabetes	9 (20.0)	4 (23.5)	0.7653
Hypertension	6 (35.3)	6 (13.3)	0.052
Hyperlipidemia	8 (47.1)	13 (28.9)	0.1652
Hyperuricemia	4 (23.5)	12 (26.7)	0.8051
Fatty liver	10 (58.8)	13 (28.9)	0.0253^a
Biomarkers
BNP (pg/mL)	22.67 ± 5.21	21.63 ± 2.95	0.86
Laboratory investigations
Serum cholesterol (mmol/L)	5.01 ± 0.26	5.06 ± 0.16	0.8666
Serum triglycerides (mmol/L)	2.13 ± 0.21	1.85 ± 0.17	0.3609
Serum HDL (mmol/L)	1.06 ± 0.06	1.17 ± 0.03	0.0766
Serum LDL (mmol/L)	3.05 ± 0.20	3.12 ± 0.13	0.7818

^aP < 0.05.

Data were given as means ± standard deviations. HFpEF: Heart failure with preserved ejection fraction; BSA: Body surface area; BMI: Body mass index; BNP: Brain natriuretic peptide; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.

Table 2 Cardiac magnetic resonance parameters of chamber size, function, epicardial adipose tissue volume of the obesity in populations with and without heart failure with preserved ejection fraction

CMR parameters	HFpEF+ (n = 17)	HFpEF- (n = 45)	P value
Conventional parameters
LVEF (%)	0.60 ± 0.03	0.64 ± 0.01	0.0797
LV mass index (g/m²)	61.38 ± 4.55	52.68 ± 1.40	0.0181^a
LVEDD (mm)	52.74 ± 1.80	50.20 ± 0.57	0.0833
LVMWT (mm)	10.32 ± 0.40	9.66 ± 0.25	0.1765
LVEDVi (mL/m²)	74.00 ± 5.52	69.16 ± 1.72	0.2716
LVESVi (mL/m²)	32.12 ± 5.87	24.84 ± 0.78	0.0592
LA AP diameter (mm)	41.37 ± 1.53	42.15 ± 0.87	0.6518
LA LR diameter (mm)	67.85 ± 2.55	70.63 ± 1.18	0.2686
Epicardial adipose tissue
EAT volume (mL)	160.00 ± 7.13	139.80 ± 5.39	0.0449^a
EATi (mL/m²)	74.20 ± 3.16	65.37 ± 2.23	0.0360^a
EAT mass (g)	147.20 ± 6.56	128.60 ± 4.98	0.0451^a
EAT mass index (g/m²)	68.26 ± 2.91	60.10 ± 2.06	0.0359^a
EAT/LA AP diameter ratio	3.56 ± 0.18	3.11 ± 0.14	0.0843
EAT/LA LR diameter ratio	2.19 ± 0.11	1.84 ± 0.08	0.0203^a
EAT/LV mass ratio	1.21 ± 0.09	1.17 ± 0.06	0.7737
EAT/LV volume ratio	0.99 ± 0.08	0.92 ± 0.04	0.4158

^aP < 0.05.

Data were given as means ± standard deviations. AP: Anterior-posterior diameter; CMR: Cardiovascular magnetic resonance; LA: Left atrial; LR: left-right diameter; LVEDVi: Left ventricular end-diastolic volume index; LVEF: Left ventricular ejection fraction; LVESVi: Left ventricular end-systolic volume index; LVMWT: LV maximal wall thickness; LVEDD: Left ventricular end-diastolic diameter; EAT: Epicardial adipose tissue; EATi: Epicardial adipose tissue index.

Table 3 Relationships between epicardial adipose tissue and morphological and functional parameters in heart failure with preserved ejection fraction positive group

Pearson’s correlation (r, P)	EAT volume (mL)	EATi (mL/m²)	EAT mass (g)	EAT mass index (g/m²)
LVEF (%)	-0.101, 0.698	0.245, 0.343	-0.101, 0.698	0.245, 0.343
LV mass index (g/m²)	0.286, 0.265	-0.039, 0.881	0.286, 0.265	-0.039, 0.882
LVEDD (mm)	0.083, 0.751	-0.102, 0.696	0.083, 0.751	-0.102, 0.697
LVMWT (mm)	0.022, 0.932	-0.314, 0.219	0.022, 0.932	-0.314, 0.219
LVEDVi (mL/m²)	-0.018, 0.946	-0.213, 0.412	-0.018, 0.946	-0.213, 0.412
LVESVi (mL/m²)	0.028, 0.916	-0.213, 0.411	0.028, 0.916	-0.213, 0.411
LA AP diameter (mm)	0.354, 0.179	0.158, 0.558	0.354, 0.179	0.158, 0.558
LA LR diameter (mm)	0.231, 0.389	0.193, 0.474	0.231, 0.389	0.193, 0.474

All P > 0.05. AP: Anterior-posterior diameter; CMR: Cardiovascular magnetic resonance; LA: Left atrial; LR, Left-right diameter; LVEDVi: Left ventricular end-diastolic volume index; LVEF: Left ventricular ejection fraction; LVESVi: Left ventricular end-systolic volume index; LVMWT: LV maximal wall thickness; LVEDD: Left ventricular end-diastolic diameter; EAT: Epicardial adipose tissue; EATi: Epicardial adipose tissue index.

Table 4 Variables associated with the heart failure with preserved ejection fraction in obesity population

Variables	Lower/upper
Variables	Univariate analysis (OR, 95%CI, P value)	Multivariate analysis (OR, 95%CI, P value)
Age (yr)	1.040 (0.994, 1.088) 0.087	1.046 (0.979, 1.117) 0.183
BMI (kg/m²)	1.057 (0.969, 1.154) 0.213
BMI > 35 kg/m²	2.812 (0.558, 14.179) 0.210
Diabetes	1.231 (0.323, 4.689) 0.761
Hypertension	3.545 (0.952, 13.201) 0.059	4.580 (1.008, 20.803) 0.049^a
LVEF (%)	0.002 (0.000, 7.482) 0.136
LVEDVi (mL/m²)	1.020 (0.984, 1.058) 0.288
LVESVi (mL/m²)	1.063 (0.958, 1.178) 0.249
LA AP diameter (mm)	0.977 (0.884, 1.080) 0.646
LA LR diameter (mm)	0.963 (0.900, 1.030) 0.267
EAT mass index (g/m²)	1.049 (1.002, 1.098) 0.042^a	0.963 (1.054, 0.880) 0.416
EAT mass (g)	1.020 (1.000, 1.041) 0.051
EATi (mL/m²)	1.045 (1.002, 1.090) 0.042^a
EAT volume (mL)	1.019 (1.000, 1.038) 0.051
EAT/LA AP diameter ratio	1.794 (0.915, 3.519) 0.089
EAT/LA LR diameter ratio	3.989 (1.171, 13.584) 0.027^a	9.226 (1.070, 79.512) 0.043^a
EAT/LV mass ratio	1.236 (0.300, 5.098) 0.770
EAT/LV volume ratio	2.299 (0.317, 16.658) 0.410

^aP < 0.05.

HDL: High-density lipoprotein; LDL: Low-density lipoprotein; EAT: Epicardial adipose tissue; EATi: Epicardial adipose tissue index; CI: Confidence interval; OR: Odds ratio.

Table 5 Intra-observer and inter-observer reproducibility for epicardial adipose tissue parameters

	Intra-observer			Inter-observer
	CV (%)	ICC	95%CI	CV (%)	ICC	95%CI
EAT volume (mL)	24.6	0.929	(0.885, 0.939)	18.4	0.900	(0.746, 0.963)
EATi (mL/m²)	23.0	0.913	(0.846, 0.951)	17.6	0.903	(0.753, 0.964)
EAT mass (g)	26.3	0.931	(0.878, 0.962)	17.9	0.900	(0.746, 0.963)
EAT mass index (g/m²)	23.7	0.913	(0.846, 0.951)	31.0	0.978	(0.941, 0.992)
EAT/LA AP diameter ratio	35.9	0.734	(0.561, 0.846)	18.5	0.882	(0.696, 0.957)
EAT/LA LR diameter ratio	28.4	0.710	(0.526, 0.831)	19.9	0.928	(0.807, 0.974)
EAT/LV mass ratio	34.7	0.870	(0.774, 0.927)	31.3	0.978	(0.941, 0.992)
EAT/LV volume ratio	29.4	0.929	(0.874, 0.961)	31.6	0.973	(0.928, 0.963)

EAT: Epicardial adipose tissue; EATi: Epicardial adipose tissue index; LA: Left atrial; AP: Anterior-posterior; LR: Left-right; LV: Left ventricular; ICC: Intra-class correlation coefficient.

Citation: Shao JW, Chen BH, Abu-Shaban K, Baiyasi A, Wu LM, Ma J. Epicardial adipose tissue in obesity with heart failure with preserved ejection fraction: Cardiovascular magnetic resonance biomarker study. World J Cardiol 2024; 16(3): 149-160
URL: https://www.wjgnet.com/1949-8462/full/v16/i3/149.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i3.149